The consensus price target hints at a 66% upside potential for Euroseas (ESEA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

The mean of analysts' price targets for California BanCorp (BCAL) points to a 25.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

The consensus price target hints at a 32.4% upside potential for Birkenstock (BIRK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

The mean of analysts' price targets for Edison International (EIX) points to a 27.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

The mean of analysts' price targets for Howard Hughes Holdings (HHH) points to a 34.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

The mean of analysts' price targets for LifeStance Health (LFST) points to a 28.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

The consensus price target hints at a 52.3% upside potential for Iridium (IRDM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

The average of price targets set by Wall Street analysts indicates a potential upside of 70.5% in Oatly Group (OTLY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

The average of price targets set by Wall Street analysts indicates a potential upside of 33.2% in Pan American Silver (PAAS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

The average of price targets set by Wall Street analysts indicates a potential upside of 32.8% in Triple Flag (TFPM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

The average of price targets set by Wall Street analysts indicates a potential upside of 48.2% in Xenon Pharmaceuticals (XENE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

The consensus price target hints at a 33.5% upside potential for First Majestic (AG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

The average of price targets set by Wall Street analysts indicates a potential upside of 35% in Veren (VRN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

The average of price targets set by Wall Street analysts indicates a potential upside of 58% in Stagwell (STGW). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

The mean of analysts' price targets for Redwood Trust (RWT) points to a 26.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

MAR'S first-quarter 2025 results are likely to benefit from robust RevPAR and ADR growth.

As Fortinet gears up to post its Q1 earnings, investors should hold their positions for now, given unattractive valuations and intensifying competition.

WGS, EBMT and CBNK made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 5, 2025.

NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQ: MRVI). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.